In one paragraphArticle in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Jennifer S HanbergDivision of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0001-6645-1144 Yuqing ZhangRheumatology and Allergy Clinical Epidemiology Research Center, Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts.
Andreas KronbichlerDepartment of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.ORCID 0000-0002-2945-2946 Anna MatyjekDepartment of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.ORCID 0000-0001-5099-6713 Carol McAlearDivision of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-0016-6866 Balazs OdlerDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Duvuru GeethaDivision of Nephrology, Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-8353-5542 Carmel HawleyDepartment of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.ORCID 0000-0002-1392-5649 Michael WalshDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0001-8292-2014 Peter A MerkelDivision of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Zachary S WallaceRheumatology and Allergy Clinical Epidemiology Research Center, Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts.
PEXIVAS investigators
Funding
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated VasculitisK23AR073334 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI WALLACE, ZACHARY SCOTT · 2018 to 2022
$948kPersonalizing AAV Management by Leveraging Big Data: Targeting Complication ClustersR03AR078938 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI WALLACE, ZACHARY SCOTT · 2021 to 2022
$189kNIAMS NIH HHS K23 AR073334NIAMS NIH HHS K23AR073334NIAMS NIH HHS R03 AR078938NIAMS NIH HHS R03AR078938
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
ANCAclinical epidemiologyepidemiology and outcomesvasculitis
Identifiers
PMID41325129
PMCPMC12889917
What OpenQuestion holds
Textmetadata
Read underepoch 390